Адъювантная химиотерапия рака молочной железы

Обложка

Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Адъювантная химиотерапия оказалась наиболее значимым достижением в лечении больных ранними стадиями рака молочной железы, а ее оптимальное применение может спасти многие жизни. Получены первые сведения о заметном улучшении результатов лечения при добавлении таксанов к стандартной терапии доксорубицином в комбинации с циклофосфамидом. Точно так же высокая активность трастузумаба (герцептина) при метастатическом раке молочной железы (РМЖ) свидетельствует о перспективе применения препарата для улучшения и адъювантного лечения. Новые химиотерапевтические агенты, проверяемые сейчас при метастатическом РМЖ, могут в недалеком будущем занять место в более эффективном адъювантном лечении. Информация, в которой крайне заинтересована сейчас клиническая онкология, касается увеличения роли прогностических и предсказывающих факторов в планировании как общей стратегии лечения, так и выборе отдельных компонентов терапии, а также манипуляции с дозами химиопрепаратов и схемами лечения.

Об авторах

В. Ф. Семиглазов

Институт онкологии имени Н.Н. Петрова

Автор, ответственный за переписку.
Email: shabanov@mail.rcom.ru

Член-корреспондент РАМН

Россия, Санкт-Петербург

Список литературы

  1. Семиглазов В.Ф., Веснин А.Г., Моисеенко В.М. Минимальный рак молочной железы. СПб.: Гиппократ, 1992. 240 с.
  2. Baselga J., Norton L. Recombinant humanized antiHER-2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts // Cancer Res. 1998. Vol. 58. P. 2825-2831.
  3. Baselga J., Tripathy D., Mendelsohn J. et al. Phase III study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer // J. Clin. Oncol. 1996. Vol. 14. Р. 737-744.
  4. Bonadonna G., Zambette M., Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes // JAMA. 1995. Vol. 273. P. 542-547.
  5. Buzzoni R., Bonadonna G., Valagussa P. et al. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three axillary lymph nodes // J. Clin. Oncol. 1991. Vol. 9. P. 2134-2140.
  6. Cannellos G. Cyclical combination chemotherapy for advanced breast cancer // Brit. Med. J. 1974. Vol. 1. P. 218-220.
  7. Cobleigh M., Vogel C., Tripathy D. et al. Multinational study of the efficacy anf safety of humanized antiHER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease //J. Clin. Oncol. 1999. Vol. 17. P. 2639-2648.
  8. Demetri G., Berry D., Norton L. et al. Clinical outcomes of node-positive breast cancer patients treated with dose-intensified Adriamycin/cyclophosphamide followed by Taxol as adjuvant systemic chemotherapy (CALGB 9141) // Proc. Amer. Soc. Clin. Oncol. 1997. Vol. 16. P. 143. Abstr. 503.
  9. Dombernowsky P., Gehl J., Boesgaard M. et al. Treatment of metastatic breast cancer with paclitaxel and doxorubicin // Semin. Oncol. 1995. Vol. 22. P. 13-17.
  10. Early Breast cancer Trialists Collaborative Group: Polychemotherapy for early breast cancer; An overview of the randomised trials // Lancet. 1998. Vol. 352. P. 930-942.
  11. Fisher B., Anderson S., DeCillis A. et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25//J. Clin. Oncol. 1999. Vol. 17. P. 3374-3388.
  12. Fisher B., Anderson S., Wickerham D. et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22//J. Clin. Oncol. 1997. Vol. 15. P. 1858-1869.
  13. Fisher B., Brown A.M., Dimitrov N.V. et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors. Results from the National Surgical Adjuvant Breast and Bowel Project B-15 // J. Clin. Oncol. 1990. Vol. 8. P. 1483-1496.
  14. Fisher B., Dignam J., Mamounas E. et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil // J. Clin. Oncol. 1996. Vol. 14. P. 1982-1992.
  15. Fisher B., Redmond C., Wickerham D.L. et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience // J. Clin. Oncol. 1989. Vol. 7. P. 572-582.
  16. Gianni L., Munzone L., Capri G. et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose finding and sequence-finding study // J. Clin. Oncol. 1995. Vol. 13. P. 2688-2699.
  17. Henderson I., Berry D., Demetri G. et al. Improved disease-free (dfs) and overall survival (os) from the addition of sequential paclitaxel (t) but not from the escalation of doxorubicin (a) dose level in the adjuvant chemotherapy of patients (pts) with nodepositive primary breast cancer // Proc. Amer. Soc. Clin Oncol. 1998. Vol. 17. P. 101a. Abstr. 390a.
  18. Hortobagyi G., BuzdarA., Champlin R. et al. Lack of efficacy of adjuvant high-dose tandem combination chemotherapy for high-risk primary breast cancer: A randomized trial // Proc. Amer. Soc. Clin. Oncol. 1998. Vol. 18. P. 123a. Abstr. 471.
  19. Hudis C. Chemotherapy for early stage breast cancer // ASCO Education Book. New Orlean, 2000. P. 266-273.
  20. Hudis C., Fornier M., Riccio L. et al. Five-year results of dose- intensive sequential adjuvant chemotherapy for women with high risk nodepositive breast cancer: A phase II study // J. Clin. Oncol. 1999. Vol. 17. P. 1118-1126.
  21. Hudis C., Seidman A., Baselga J. et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy // J. Clin. Oncol. 1999. Vol. 17. P. 93-100.
  22. Hudis C., Seidman A., Paton V. et al. Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials // Breast Cancer Res. Treat. 1998. Vol. 50. P. 232. Abstr. 24
  23. Joensuu H., Holli K., Heikkinen M. et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial // J. Clin. Oncol. 1998. Vol. 16. P. 3720- 3730.
  24. Norton L., Simon R. Tumor size, sensitivity of therapy, and design of treatment schedules // Cancer Treat. Rep. 1977. Vol. 61. P. 1307-1315.
  25. Norton L., Slamon D., Leyland-Jones B. et al. Overall survival advantage to simultaneous chemotherapy plus the humanized Anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer // Proc. Amer. Soc. Clin. Oncol. 1999. Vol. 18. P. 127a. Abstr. 483.
  26. Paik S., Bryant J., Park C. et al. erB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer // J. Natl. Cancer Inst. 1998. Vol. 30. P. 1361-1370.
  27. Peters W., Rosner G., Vredenburgh J. et al. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten of more axillary lymph nodes: Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 // Proc. Amer. Soc. Clin. Oncol. 1999. Vol. 18. P.la. Abstr. 2.
  28. Rodenhuis S., Richel D., van der Wall E. et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph node involvement // Lancet. 1998. Vol. 352. P. 515- 521.
  29. Schrama J., Rodenhuis S. Dose-intensive chemotherapy for locally advanced breast cancer // Cur. Oncol. Rep. 1999. Vol. 1. P. 21-30.
  30. Seidman A. The emerging role of paclitaxel in breast cancer therapy // Clin. Cancer Res. 1995. Vol. 1. P. 247-256.
  31. Slamon D., Leyland-Jones B., Shak S. et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/mbc) markedly increases anticancer activity: A randomozed, multinational controlled phase III trial // Proc. Amer. Clin. Oncol. 1998. Vol. 17. P. 98a. Abstr. 377.
  32. Sledge G., Neuberg D., Ingle J. et al. Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + +paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial // Proc. Am. Soc. Clin. Oncol. 1997. Vol. 16. № 1a. Abstr. 2.
  33. Stadmauer E., O'Neil A., Goldstein L. et al. Phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia Intergroup Study // Proc. Amer. Soc. Clin. Oncol. 1999. Vol. 18. P. 1a. Abstr. 1.
  34. Tabar L., Duffy S., Vitak B. et al. The natural history of breast carcinima: what have we learned from screening? // Cancer. 1999. Vol. 86. P. 449-462.
  35. Tabar L., Fagerberg G., Day N. The results of periodic one-view mammography screening in a randomized controlled trial in Sweden // Screening for breast cancer / Ed. by N.Day and A. Miller. Toromto, 1988. P. 39-44.
  36. The Scandinavian Breast Cancer Study Group: Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy // Proc. Amer. Soc. Clin. Oncol. 1999. Vol. 18. P. 2a. Abstr. 3.
  37. Thor A., Berry D., Budman D. et al. erB-2, p-53 and efficacy of adjuvant therapy in lymph nodepositive breast cancer // J. Natl. Cancer Inst. 1998. Vol. 90. P. 1346-1360.
  38. Wilcox W.S., Griswold D.P., Laster W.R. Jr. et al. Experimental evaluation of potential anticancer agents:XVII. Kinetics of growth and regression after treatment of certain solid tumors // Cancer Chemother. Rep. 1965. Vol. 47. P. 27-39.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Эко-Вектор, 2001


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.